Impact of beta‐amyloid oligomers on in vivo brain glucose metabolism

Background The deposition of β‐amyloid (Aβ) plaques is a classical neuropathological feature of Alzheimer’s disease (AD). Currently, it is believed that intermediate products of the Aβ fibrillogenesis process, like the β‐amyloid oligomers (AβOs), are the most toxic forms, and are involved in neurode...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alzheimer's & dementia 2025-01, Vol.20 (Suppl 8), p.n/a
Hauptverfasser: da Rocha, Andreia Silva, Fontana, Igor C., Peixoto, Guilherme G. Schu, Souza, Amanda S, Venturin, Gianina Teribele, Greggio, Samuel, Forny‐Germano, Leticia, Lourenco, Mychael V, Rosa‐Neto, Pedro, Souza, Diogo O., da Costa, Jaderson Costa, Ferreira, Sergio T, Zimmer, Eduardo R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue Suppl 8
container_start_page
container_title Alzheimer's & dementia
container_volume 20
creator da Rocha, Andreia Silva
Fontana, Igor C.
Peixoto, Guilherme G. Schu
Souza, Amanda S
Venturin, Gianina Teribele
Greggio, Samuel
Forny‐Germano, Leticia
Lourenco, Mychael V
Rosa‐Neto, Pedro
Souza, Diogo O.
da Costa, Jaderson Costa
Ferreira, Sergio T
Zimmer, Eduardo R.
description Background The deposition of β‐amyloid (Aβ) plaques is a classical neuropathological feature of Alzheimer’s disease (AD). Currently, it is believed that intermediate products of the Aβ fibrillogenesis process, like the β‐amyloid oligomers (AβOs), are the most toxic forms, and are involved in neurodegenerative processes in AD. The evaluation of cerebral glucose metabolism in patients with β‐amyloid plaque deposition using [18F]FDG‐PET has been used as a marker of neurodegeneration in AD. However, little is understood about AβOs' impact on glucose metabolism prior to Aβ plaques formation. The aim of this study was to evaluate the impact of the intracerebroventricular infusion of AβOs on in vivo glucose metabolism via [18F]FDG‐PET. Method Male Swiss mice (3‐month‐old, n = 20 per group) were divided into three groups: Vehicle, AβOs 10pmol, and AβOs 100pmol. Vehicle/AβOs were infused into mice’ right ventricle using the freehand technique after brief isoflurane anesthesia. [18F]FDG‐PET scans were performed 24h after AβOs infusion. The same animals underwent the Novel Object Recognition (NOR) task 24h after scanning. The images were processed and analyzed using MINC tools. Metabolic networks were built by computing Pearson correlation coefficients based on 2,000 bootstrap samples and FDR corrected (P
doi_str_mv 10.1002/alz.095067
format Article
fullrecord <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11714140</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ALZ095067</sourcerecordid><originalsourceid>FETCH-LOGICAL-p987-3d68a946f514f948ae7a6841a396a32f62fff63fc7b4e5d152d2cea6a7161433</originalsourceid><addsrcrecordid>eNpVkM1Kw0AUhQdRsFY3PsG8QOrcyfwkKynFaqHgQlduhptkpo5kMiFpK3XlI_iMPomRSMHV_eCe8y0OIdfAZsAYv8H6Y8ZyyZQ-IROQkieS6_z0yIqdk4u-f2NMsAzkhCxXocVyS6Ojhd3i9-cXhkMdfUVj7Tcx2K6nsaG-oXu_j7TocMBNvStjb2kYGsWQ68MlOXNY9_bq707J0_LuefGQrB_vV4v5OmnzTCdppTLMhXIShMtFhlajygRgmitMuVPcOadSV-pCWFmB5BUvLSrUoECk6ZTcjtZ2VwRblbbZdlibtvMBu4OJ6M3_T-NfzSbuDYAGAYINBhgN7762h2MTmPmdzwzzmXE-M1-_jJT-AEwTZ_M</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Impact of beta‐amyloid oligomers on in vivo brain glucose metabolism</title><source>Wiley Online Library Journals Frontfile Complete</source><source>PubMed Central Open Access</source><source>Wiley-Blackwell Open Access Titles</source><source>PubMed Central</source><creator>da Rocha, Andreia Silva ; Fontana, Igor C. ; Peixoto, Guilherme G. Schu ; Souza, Amanda S ; Venturin, Gianina Teribele ; Greggio, Samuel ; Forny‐Germano, Leticia ; Lourenco, Mychael V ; Rosa‐Neto, Pedro ; Souza, Diogo O. ; da Costa, Jaderson Costa ; Ferreira, Sergio T ; Zimmer, Eduardo R.</creator><creatorcontrib>da Rocha, Andreia Silva ; Fontana, Igor C. ; Peixoto, Guilherme G. Schu ; Souza, Amanda S ; Venturin, Gianina Teribele ; Greggio, Samuel ; Forny‐Germano, Leticia ; Lourenco, Mychael V ; Rosa‐Neto, Pedro ; Souza, Diogo O. ; da Costa, Jaderson Costa ; Ferreira, Sergio T ; Zimmer, Eduardo R.</creatorcontrib><description>Background The deposition of β‐amyloid (Aβ) plaques is a classical neuropathological feature of Alzheimer’s disease (AD). Currently, it is believed that intermediate products of the Aβ fibrillogenesis process, like the β‐amyloid oligomers (AβOs), are the most toxic forms, and are involved in neurodegenerative processes in AD. The evaluation of cerebral glucose metabolism in patients with β‐amyloid plaque deposition using [18F]FDG‐PET has been used as a marker of neurodegeneration in AD. However, little is understood about AβOs' impact on glucose metabolism prior to Aβ plaques formation. The aim of this study was to evaluate the impact of the intracerebroventricular infusion of AβOs on in vivo glucose metabolism via [18F]FDG‐PET. Method Male Swiss mice (3‐month‐old, n = 20 per group) were divided into three groups: Vehicle, AβOs 10pmol, and AβOs 100pmol. Vehicle/AβOs were infused into mice’ right ventricle using the freehand technique after brief isoflurane anesthesia. [18F]FDG‐PET scans were performed 24h after AβOs infusion. The same animals underwent the Novel Object Recognition (NOR) task 24h after scanning. The images were processed and analyzed using MINC tools. Metabolic networks were built by computing Pearson correlation coefficients based on 2,000 bootstrap samples and FDR corrected (P&lt;0.05). See Fig. 1a, for a experimental design illustration. Results AβOs induced dose‐dependent brain glucose hypometabolism (Fig. 1b) and metabolic network disturbances. Voxel‐wise percentage change analysis revealed moderate reductions in glucose brain metabolism (5% to 15%) following infusion of 10pmol AβOs, whereas 100 pmol AβOs led to widespread and substantial reductions of up to 25% (Fig. 1c). T‐statistical voxel‐wise analysis indicated statistically significant brain glucose hypometabolism only in the 100pmol group (Fig. 1d). The low‐dose AβOs (10pmol) induced brain inter‐region metabolic hyperconnectivity, while the 100 pmol dose caused hypoconnectivity (Fig. 1e). Furthermore, both AβOs infusion groups exhibited impaired recognition memory in the NOR task (Fig. 1f). Conclusion Our results are the first demonstration of AβOs causing in vivo glucose hypometabolism and metabolic network disturbances in the absence of plaques. These findings point to an early impact of AβOs on glucose metabolism, independent of β‐amyloid plaque formation. While the molecular pathways underlying this effect require further investigation, they may represent important AD pathophysiological mechanisms and potential targets for therapeutic intervention.</description><identifier>ISSN: 1552-5260</identifier><identifier>EISSN: 1552-5279</identifier><identifier>DOI: 10.1002/alz.095067</identifier><language>eng</language><publisher>Hoboken: John Wiley and Sons Inc</publisher><subject>Basic Science and Pathogenesis</subject><ispartof>Alzheimer's &amp; dementia, 2025-01, Vol.20 (Suppl 8), p.n/a</ispartof><rights>2024 The Alzheimer's Association. published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11714140/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11714140/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,1414,11549,27911,27912,45561,45562,46039,46463,53778,53780</link.rule.ids></links><search><creatorcontrib>da Rocha, Andreia Silva</creatorcontrib><creatorcontrib>Fontana, Igor C.</creatorcontrib><creatorcontrib>Peixoto, Guilherme G. Schu</creatorcontrib><creatorcontrib>Souza, Amanda S</creatorcontrib><creatorcontrib>Venturin, Gianina Teribele</creatorcontrib><creatorcontrib>Greggio, Samuel</creatorcontrib><creatorcontrib>Forny‐Germano, Leticia</creatorcontrib><creatorcontrib>Lourenco, Mychael V</creatorcontrib><creatorcontrib>Rosa‐Neto, Pedro</creatorcontrib><creatorcontrib>Souza, Diogo O.</creatorcontrib><creatorcontrib>da Costa, Jaderson Costa</creatorcontrib><creatorcontrib>Ferreira, Sergio T</creatorcontrib><creatorcontrib>Zimmer, Eduardo R.</creatorcontrib><title>Impact of beta‐amyloid oligomers on in vivo brain glucose metabolism</title><title>Alzheimer's &amp; dementia</title><description>Background The deposition of β‐amyloid (Aβ) plaques is a classical neuropathological feature of Alzheimer’s disease (AD). Currently, it is believed that intermediate products of the Aβ fibrillogenesis process, like the β‐amyloid oligomers (AβOs), are the most toxic forms, and are involved in neurodegenerative processes in AD. The evaluation of cerebral glucose metabolism in patients with β‐amyloid plaque deposition using [18F]FDG‐PET has been used as a marker of neurodegeneration in AD. However, little is understood about AβOs' impact on glucose metabolism prior to Aβ plaques formation. The aim of this study was to evaluate the impact of the intracerebroventricular infusion of AβOs on in vivo glucose metabolism via [18F]FDG‐PET. Method Male Swiss mice (3‐month‐old, n = 20 per group) were divided into three groups: Vehicle, AβOs 10pmol, and AβOs 100pmol. Vehicle/AβOs were infused into mice’ right ventricle using the freehand technique after brief isoflurane anesthesia. [18F]FDG‐PET scans were performed 24h after AβOs infusion. The same animals underwent the Novel Object Recognition (NOR) task 24h after scanning. The images were processed and analyzed using MINC tools. Metabolic networks were built by computing Pearson correlation coefficients based on 2,000 bootstrap samples and FDR corrected (P&lt;0.05). See Fig. 1a, for a experimental design illustration. Results AβOs induced dose‐dependent brain glucose hypometabolism (Fig. 1b) and metabolic network disturbances. Voxel‐wise percentage change analysis revealed moderate reductions in glucose brain metabolism (5% to 15%) following infusion of 10pmol AβOs, whereas 100 pmol AβOs led to widespread and substantial reductions of up to 25% (Fig. 1c). T‐statistical voxel‐wise analysis indicated statistically significant brain glucose hypometabolism only in the 100pmol group (Fig. 1d). The low‐dose AβOs (10pmol) induced brain inter‐region metabolic hyperconnectivity, while the 100 pmol dose caused hypoconnectivity (Fig. 1e). Furthermore, both AβOs infusion groups exhibited impaired recognition memory in the NOR task (Fig. 1f). Conclusion Our results are the first demonstration of AβOs causing in vivo glucose hypometabolism and metabolic network disturbances in the absence of plaques. These findings point to an early impact of AβOs on glucose metabolism, independent of β‐amyloid plaque formation. While the molecular pathways underlying this effect require further investigation, they may represent important AD pathophysiological mechanisms and potential targets for therapeutic intervention.</description><subject>Basic Science and Pathogenesis</subject><issn>1552-5260</issn><issn>1552-5279</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNpVkM1Kw0AUhQdRsFY3PsG8QOrcyfwkKynFaqHgQlduhptkpo5kMiFpK3XlI_iMPomRSMHV_eCe8y0OIdfAZsAYv8H6Y8ZyyZQ-IROQkieS6_z0yIqdk4u-f2NMsAzkhCxXocVyS6Ojhd3i9-cXhkMdfUVj7Tcx2K6nsaG-oXu_j7TocMBNvStjb2kYGsWQ68MlOXNY9_bq707J0_LuefGQrB_vV4v5OmnzTCdppTLMhXIShMtFhlajygRgmitMuVPcOadSV-pCWFmB5BUvLSrUoECk6ZTcjtZ2VwRblbbZdlibtvMBu4OJ6M3_T-NfzSbuDYAGAYINBhgN7762h2MTmPmdzwzzmXE-M1-_jJT-AEwTZ_M</recordid><startdate>20250109</startdate><enddate>20250109</enddate><creator>da Rocha, Andreia Silva</creator><creator>Fontana, Igor C.</creator><creator>Peixoto, Guilherme G. Schu</creator><creator>Souza, Amanda S</creator><creator>Venturin, Gianina Teribele</creator><creator>Greggio, Samuel</creator><creator>Forny‐Germano, Leticia</creator><creator>Lourenco, Mychael V</creator><creator>Rosa‐Neto, Pedro</creator><creator>Souza, Diogo O.</creator><creator>da Costa, Jaderson Costa</creator><creator>Ferreira, Sergio T</creator><creator>Zimmer, Eduardo R.</creator><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>5PM</scope></search><sort><creationdate>20250109</creationdate><title>Impact of beta‐amyloid oligomers on in vivo brain glucose metabolism</title><author>da Rocha, Andreia Silva ; Fontana, Igor C. ; Peixoto, Guilherme G. Schu ; Souza, Amanda S ; Venturin, Gianina Teribele ; Greggio, Samuel ; Forny‐Germano, Leticia ; Lourenco, Mychael V ; Rosa‐Neto, Pedro ; Souza, Diogo O. ; da Costa, Jaderson Costa ; Ferreira, Sergio T ; Zimmer, Eduardo R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p987-3d68a946f514f948ae7a6841a396a32f62fff63fc7b4e5d152d2cea6a7161433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Basic Science and Pathogenesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>da Rocha, Andreia Silva</creatorcontrib><creatorcontrib>Fontana, Igor C.</creatorcontrib><creatorcontrib>Peixoto, Guilherme G. Schu</creatorcontrib><creatorcontrib>Souza, Amanda S</creatorcontrib><creatorcontrib>Venturin, Gianina Teribele</creatorcontrib><creatorcontrib>Greggio, Samuel</creatorcontrib><creatorcontrib>Forny‐Germano, Leticia</creatorcontrib><creatorcontrib>Lourenco, Mychael V</creatorcontrib><creatorcontrib>Rosa‐Neto, Pedro</creatorcontrib><creatorcontrib>Souza, Diogo O.</creatorcontrib><creatorcontrib>da Costa, Jaderson Costa</creatorcontrib><creatorcontrib>Ferreira, Sergio T</creatorcontrib><creatorcontrib>Zimmer, Eduardo R.</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Alzheimer's &amp; dementia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>da Rocha, Andreia Silva</au><au>Fontana, Igor C.</au><au>Peixoto, Guilherme G. Schu</au><au>Souza, Amanda S</au><au>Venturin, Gianina Teribele</au><au>Greggio, Samuel</au><au>Forny‐Germano, Leticia</au><au>Lourenco, Mychael V</au><au>Rosa‐Neto, Pedro</au><au>Souza, Diogo O.</au><au>da Costa, Jaderson Costa</au><au>Ferreira, Sergio T</au><au>Zimmer, Eduardo R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of beta‐amyloid oligomers on in vivo brain glucose metabolism</atitle><jtitle>Alzheimer's &amp; dementia</jtitle><date>2025-01-09</date><risdate>2025</risdate><volume>20</volume><issue>Suppl 8</issue><epage>n/a</epage><issn>1552-5260</issn><eissn>1552-5279</eissn><abstract>Background The deposition of β‐amyloid (Aβ) plaques is a classical neuropathological feature of Alzheimer’s disease (AD). Currently, it is believed that intermediate products of the Aβ fibrillogenesis process, like the β‐amyloid oligomers (AβOs), are the most toxic forms, and are involved in neurodegenerative processes in AD. The evaluation of cerebral glucose metabolism in patients with β‐amyloid plaque deposition using [18F]FDG‐PET has been used as a marker of neurodegeneration in AD. However, little is understood about AβOs' impact on glucose metabolism prior to Aβ plaques formation. The aim of this study was to evaluate the impact of the intracerebroventricular infusion of AβOs on in vivo glucose metabolism via [18F]FDG‐PET. Method Male Swiss mice (3‐month‐old, n = 20 per group) were divided into three groups: Vehicle, AβOs 10pmol, and AβOs 100pmol. Vehicle/AβOs were infused into mice’ right ventricle using the freehand technique after brief isoflurane anesthesia. [18F]FDG‐PET scans were performed 24h after AβOs infusion. The same animals underwent the Novel Object Recognition (NOR) task 24h after scanning. The images were processed and analyzed using MINC tools. Metabolic networks were built by computing Pearson correlation coefficients based on 2,000 bootstrap samples and FDR corrected (P&lt;0.05). See Fig. 1a, for a experimental design illustration. Results AβOs induced dose‐dependent brain glucose hypometabolism (Fig. 1b) and metabolic network disturbances. Voxel‐wise percentage change analysis revealed moderate reductions in glucose brain metabolism (5% to 15%) following infusion of 10pmol AβOs, whereas 100 pmol AβOs led to widespread and substantial reductions of up to 25% (Fig. 1c). T‐statistical voxel‐wise analysis indicated statistically significant brain glucose hypometabolism only in the 100pmol group (Fig. 1d). The low‐dose AβOs (10pmol) induced brain inter‐region metabolic hyperconnectivity, while the 100 pmol dose caused hypoconnectivity (Fig. 1e). Furthermore, both AβOs infusion groups exhibited impaired recognition memory in the NOR task (Fig. 1f). Conclusion Our results are the first demonstration of AβOs causing in vivo glucose hypometabolism and metabolic network disturbances in the absence of plaques. These findings point to an early impact of AβOs on glucose metabolism, independent of β‐amyloid plaque formation. While the molecular pathways underlying this effect require further investigation, they may represent important AD pathophysiological mechanisms and potential targets for therapeutic intervention.</abstract><cop>Hoboken</cop><pub>John Wiley and Sons Inc</pub><doi>10.1002/alz.095067</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1552-5260
ispartof Alzheimer's & dementia, 2025-01, Vol.20 (Suppl 8), p.n/a
issn 1552-5260
1552-5279
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11714140
source Wiley Online Library Journals Frontfile Complete; PubMed Central Open Access; Wiley-Blackwell Open Access Titles; PubMed Central
subjects Basic Science and Pathogenesis
title Impact of beta‐amyloid oligomers on in vivo brain glucose metabolism
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T12%3A53%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20beta%E2%80%90amyloid%20oligomers%20on%20in%20vivo%20brain%20glucose%20metabolism&rft.jtitle=Alzheimer's%20&%20dementia&rft.au=da%20Rocha,%20Andreia%20Silva&rft.date=2025-01-09&rft.volume=20&rft.issue=Suppl%208&rft.epage=n/a&rft.issn=1552-5260&rft.eissn=1552-5279&rft_id=info:doi/10.1002/alz.095067&rft_dat=%3Cwiley_pubme%3EALZ095067%3C/wiley_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true